Dal vaccino bivalente al 9-valente - Prof. Baldo - TS 12/06/2017
-_Public_assessment_report/human/003852/WC500189113.pdf Incidenza delle lesioni confronto Endpoint HPV9v (N=7099) HPV4v (N=7105) Casi/n (95% CI)* Casi/n (95% CI)* HPV 16/18 CIN 2/3 or AIS VIN 2/3 VaIN 2/3 1 / 5715 0 / 5762 0 / 5762 0.6 (0.0, 3.3) 0.0 (0.0, 2.0) 0.0 (0.0, 2.0) 0 / 5732 0 / 5789 2 / 5789 0.0 ...